ORIGINAL RESEARCH article
Front. Public Health
Sec. Children and Health
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1560003
Global, Regional, and National Epidemiology of Childhood Burkitt Lymphoma from 1990 to 2021: Statistical Analysis of Incidence, Mortality, and DALYs
Provisionally accepted
- 1Department of Pediatric Surgery, Suining Central Hospital, Suining, China
- 2Department of Radiology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China
- 3School of Public Health, Kunming Medical University, Kunming, Yunnan Province, China
- 4Ganzhou Vocational and Technical College, Ganzhou, Jiangxi Province, China
- 5Department of Radiology, Yunnan Cancer Hospital, Kunming, Yunnan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This study examines the trends in incidence, mortality, and disability-adjusted life years (DALYs), as well as the estimated annual percentage change (EAPC) associated with childhood Burkitt Lymphoma within this demographic from 1990 to 2021.Methods: The 2021 Global Burden of Disease, Injuries, and Risk Factors Study (GBD) analytical tools were utilized to evaluate the incidence, mortality, and DALYs associated with childhood Burkitt Lymphoma in individuals aged 0–14 years. This analysis incorporated variables such as age, sex, region, and sociodemographic index (SDI), utilizing data from 204 countries or regions. A comprehensive examination of health disparities was undertaken to investigate variations in mortality and DALYs among different population groups. Additionally, the Bayesian age-period-cohort model was employed to forecast incidence, mortality, and DALYs through the year 2035.Results: In 2021, a total of 4,083 cases of childhood Burkitt Lymphoma were documented globally. This represents an increase from 2,800 cases reported in 1990, with a 95% uncertainty interval (UI) ranging from 1,609.001 to 3,989.282, to 4,083 cases in 2021 (95% UI, 2,619.594 to 5,376.872), indicating a 31.45% rise over the period. During this 30-year span, the global incidence rate escalated from 0.172 per 100,000 individuals in 1990 (95% UI, 0.099 to 0.245) to 0.216 per 100,000 individuals in 2021 (95% UI, 0.138 to 0.285). Concurrently, the mortality rate associated with childhood Burkitt Lymphoma increased from 0.152 per 100,000 individuals in 1990 (95% UI, 0.079 to 0.224) to 0.163 per 100,000 individuals in 2021 (95% UI, 0.100 to 0.216). The highest incidence in 2021 was recorded in Sub-Saharan East Africa, while Sub-Saharan Southern Africa experienced the most pronounced increase in incidence, with an annual percent change (APC) of 3.226% (95% confidence interval [CI]: 2.092%–4.373%). The age group most affected was children aged 5–9 years, who constituted 33.3% of the cases.Conclusion: Between 1990 and 2021, there was a notable rise in the incidence of childhood Burkitt Lymphoma, with a pronounced increase observed in Sub-Saharan Africa. The age group of 5–9 years exhibited the highest incidence and mortality rates, underscoring the critical need for early diagnosis and intervention.
Keywords: Children, Burkitt Lymphoma, Global burden of disease, Disability-adjusted life years, Estimated annual percentage changes
Received: 31 Jan 2025; Accepted: 24 Jun 2025.
Copyright: © 2025 Zou, Jiang, Liu, Chen, Jin and Pu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hongjiang Pu, Department of Radiology, Yunnan Cancer Hospital, Kunming, Yunnan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.